Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946371 | 1.00 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1LMNA | |
| SCHEMBL10183365 | 1.00 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1LMNA | |
| SCHEMBL13030145 | 1.00 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1LMNA | |
| SCHEMBL21067741 | 0.86 | TYMS (0.58) | TYMS | |
| SCHEMBL21067742 | 0.86 | TYMS (0.58) | TYMS | |
| SCHEMBL13030152 | 0.81 | SLC29A1 (0.47) | SLC29A1TYMSADRB1DNMT1CYP1A2 | |
| SCHEMBL14534827 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL14084325 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL1062447 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL29446054 | 0.81 | LMNA (0.49) | SLC29A1LMNASMN1; SMN2CYP1A2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2017-10-05 | — | — | US | disclosed |
| US-9708615-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9222091-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140316124-A1 | MODIDIFED iRNA AGENTS | BANK OF AMERICA, N.A. | 2014-10-23 | — | — | US | disclosed |
| US-20140309411-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2014-10-16 | — | — | US | disclosed |
| US-8809516-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809516-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8796436-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130144048-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130144048-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8445665-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8420799-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1615611-B1 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20110092565-A1 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100240881-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | SLC29A1 2315/4885TYMS 3058/4885ADRB1 2639/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | SLC29A1 3876/4885TYMS 1087/4885ADRB1 4011/4885 |
| US-20110092565-A1 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | SNCA, PARK7, NLN | SLC29A1 2315/4885TYMS 3058/4885ADRB1 2639/4885 |
| US-20100240881-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | SLC29A1 3003/4885TYMS 2371/4885ADRB1 4624/4885 |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | SLC29A1 3003/4885TYMS 2371/4885ADRB1 4624/4885 |
| US-20130144048-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | SLC29A1 3003/4885TYMS 2371/4885ADRB1 4624/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | SLC29A1 1492/4885TYMS 902/4885ADRB1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.